Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | KHK | P50053 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116963 | 0.82 | TDP1 (0.35) | — | |
| SCHEMBL30861998 | 0.75 | ALDH1A1 (0.35) | HTTALDH1A1KHK | |
| SCHEMBL22655948 | 0.75 | TDP1 (0.31) | — | |
| SCHEMBL259072 | 0.75 | PDE10A (0.52) | HTTSMN1; SMN2ADORA1ALDH1A1PDE10A | |
| SCHEMBL20267103 | 0.75 | ALDH1A1 (0.35) | HTTALDH1A1KHK | |
| SCHEMBL29484711 | 0.75 | HTT (0.35) | HTTSMN1; SMN2ADORA1ALDH1A1PDE10A | |
| SCHEMBL14165804 | 0.75 | HTT (0.35) | HTTSMN1; SMN2ADORA1ALDH1A1PDE10A | |
| SCHEMBL9160684 | 0.75 | HSP90B1 (0.33) | ADORA1KHKADORA2A | |
| SCHEMBL116212 | 0.75 | HTT (0.37) | HTTSMN1; SMN2ADORA1ALDH1A1PDE10A | |
| SCHEMBL31484438 | 0.73 | KMT2A (0.44) | HTTSMN1; SMN2ADORA1ALDH1A1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| EP-1968956-A2 | CALCIUM CHANNEL ANTAGONISTS | Icagen, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1968596-A2 | CALCIUM CHANNEL ANTAGONISTS | Icagen, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20070197523-A1 | CALCIUM CHANNEL ANTAGONISTS | ICAGEN, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070173504-A1 | CALCIUM CHANNEL ANTAGONISTS | ICAGEN, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| WO-2007075852-A2 | CALCIUM CHANNEL ANTAGONISTS | ICAGEN, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007073497-A2 | CALCIUM CHANNEL ANTAGONISTS | ICAGEN, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | HTT 1270/4885SMN1; SMN2 1834/4885ADORA1 3744/4885 |
| US-20070173504-A1 | CALCIUM CHANNEL ANTAGONISTS | CACNA1E, CACNA1H, CACNA1G | HTT 948/4885SMN1; SMN2 1304/4885ADORA1 627/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | HTT 1270/4885SMN1; SMN2 1834/4885ADORA1 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.